Imperva Inc (IMPV) Shares Bought by Rothschild Asset Management Inc.
Rothschild Asset Management Inc. raised its holdings in Imperva Inc (NASDAQ:IMPV) by 18.4% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 594,441 shares of the software maker’s stock after buying an additional 92,349 shares during the period. Rothschild Asset Management Inc. owned about 1.71% of Imperva worth $28,682,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in the business. First Trust Advisors LP raised its stake in Imperva by 86.8% in the second quarter. First Trust Advisors LP now owns 477,533 shares of the software maker’s stock valued at $23,041,000 after buying an additional 221,932 shares during the period. Emerald Advisers Inc. PA grew its position in shares of Imperva by 27.5% in the second quarter. Emerald Advisers Inc. PA now owns 424,501 shares of the software maker’s stock valued at $20,482,000 after purchasing an additional 91,680 shares during the last quarter. Legal & General Group Plc grew its position in shares of Imperva by 2,341.6% in the first quarter. Legal & General Group Plc now owns 406,445 shares of the software maker’s stock valued at $17,599,000 after purchasing an additional 389,798 shares during the last quarter. Emerald Mutual Fund Advisers Trust grew its position in shares of Imperva by 31.6% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 375,919 shares of the software maker’s stock valued at $18,138,000 after purchasing an additional 90,158 shares during the last quarter. Finally, Broadview Advisors LLC grew its position in shares of Imperva by 10.7% in the second quarter. Broadview Advisors LLC now owns 283,975 shares of the software maker’s stock valued at $13,702,000 after purchasing an additional 27,450 shares during the last quarter.
Several equities analysts have recently commented on IMPV shares. BidaskClub raised Imperva from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, July 17th. Evercore ISI reaffirmed a “buy” rating and issued a $56.00 target price on shares of Imperva in a research report on Friday, April 27th. Oppenheimer upped their target price on Imperva from $55.00 to $60.00 and gave the company an “outperform” rating in a research report on Monday, June 18th. Stephens upped their target price on Imperva from $61.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, June 14th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and issued a $54.00 target price on shares of Imperva in a research report on Monday, April 23rd. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating and seven have assigned a buy rating to the company’s stock. Imperva currently has a consensus rating of “Hold” and an average price target of $54.00.
Imperva (NASDAQ:IMPV) last issued its quarterly earnings results on Thursday, July 26th. The software maker reported ($0.26) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.07. The business had revenue of $84.80 million for the quarter, compared to the consensus estimate of $87.22 million. Imperva had a negative return on equity of 6.92% and a negative net margin of 8.59%. The firm’s quarterly revenue was up 13.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 earnings per share. sell-side analysts expect that Imperva Inc will post -1.15 EPS for the current fiscal year.
Imperva Company Profile
Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.
Read More: Dividend Stocks – Are They Right For You?
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.